Document Detail

Evaluation of the Safety and Efficacy of Combination Chemotherapy with Vinorelbine and Platinum Agents for Patients with Non-small Cell Lung Cancer with Interstitial Lung Disease.
MedLine Citation:
PMID:  23225454     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: Acute chemotherapy-associated exacerbation of interstitial lung disease (ILD) can occur in patients with non-small cell lung cancer (NSCLC). The safety and efficacy of cytotoxic chemotherapy has not yet been established for NSCLC with ILD. Thus, patients with advanced NSCLC with ILD usually receive only best supportive care. The aim of this study was to assess the safety and efficacy profiles of the combination chemotherapy of vinorelbine and a platinum agent in patients with advanced NSCLC with ILD.
PATIENTS AND METHODS: Nineteen patients with advanced NSCLC with ILD treated with vinorelbine and a platinum agent, either cisplatin or carboplatin, were retrospectively reviewed to examine acute exacerbation of ILD, toxicity, response rate, and survival time. Additionally, possible predictive factors for acute chemotherapy-associated exacerbation of ILD were analyzed.
RESULTS: The response rate was 42.1%, the progression-free survival time was 4.4 months, the median survival time was 7.4 months, and the one-year survival rate was 36.8%. Neutropenia was the most frequent grade 3 to 4 toxicity and it occurred in 63.2% of patients. Acute chemotherapy-associated exacerbation of ILD occurred in three patients (15.8%) and caused the death of one of these patients (5.3%). No variables were identified as being predictive factors for acute chemotherapy-associated exacerbation of ILD.
CONCLUSION: The combination chemotherapy with vinorelbine and a platinum agent can be considered as a treatment option for patients with advanced NSCLC with ILD, with careful management after sufficient evaluation of the risks and the benefits.
Kentaro Okuda; Takashi Hirose; Yasunari Oki; Yasunori Murata; Sojiro Kusumoto; Tomohide Sugiyama; Hiroo Ishida; Takao Shirai; Masanao Nakashima; Toshimitsu Yamaoka; Tsukasa Ohnishi; Tohru Ohmori
Related Documents :
23608814 - Impact of pet staging in limited-stage small-cell lung cancer.
2802034 - Management of advanced glottic carcinomas.
21930984 - Postoperative clinical radiosensitivity in patients with fanconi anemia and head and ne...
23675254 - Tetrandrine combined with gemcitabine and cisplatin for patients with advanced non-smal...
16961284 - Serum vascular endothelial growth factor-c and vascular endothelial growth factor level...
2288054 - Prognostication of bladder carcinoma by immunohistochemistry: refined and combined anal...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  32     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  5475-80     Citation Subset:  IM    
Division of Respiratory Medicine and Allergology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa, Tokyo 142-8666, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Review on the Annual Cancer Risk of Barrett's Esophagus in Persons with Symptoms of Gastroesophageal...
Next Document:  Adverse Pathological Findings in Needle Biopsy Gleason Score 6 Prostate Cancers with Low and Interme...